Zurück zur Übersicht
| Clinical transplantation. 2016 May 24. doi: 10.1111/ctr.12764 |
| Lung transplantation in patients with incidental early stage lung cancer - institutional experience of a high volume center. |
| Klikovits T1, Lambers C2, Ghanim B3, Dome B4, Murakoezy G5, Zöchbauer-Müller S6, Waseda R7, Aigner C8, Lang G9, Taghavi S10, Klepetko W11, Jaksch P12, Hoda MA13 |
 Author information
|
|
Abstract BACKGROUND: Incidentally discovered lung cancers in lung transplant (LuTX) recipients are rare but may affect outcome. We aim to report our single center experience with incidence, management and survival of patients with previously unverified primary lung cancer discovered at the time of LuTX. METHODS: A total of 1262 patients undergoing LuTX between 1989 and 2012 were retrospectively analysed in our prospective database. RESULTS: Patients identified were 6 men and 5 women with a mean age of 54.4 ± 9.9 years. The indication for LuTX was COPD (n=9), pulmonary fibrosis (n=1) and cystic fibrosis (n=1). Histological diagnosis of the explanted lung revealed adenocarcinoma in 6, squamous cell carcinoma in 3 and lepidic predominant adenocarcinoma in 2 cases, respectively. Staging revealed stage IA (pT1a/b pN0) in 8 and IB (pT2a pN0) in 2 cases and 1 patient in stage IIA (pT1b pN1). Subsequent cancer staging after LuTX revealed no metastasis. Immunosuppression was adjusted and no adjuvant chemo- or radiotherapy was administered. The 5-year survival rate was 90.5% with no detection of recurrence. CONCLUSION: In patients with incidentally detected early stage lung cancer at the time of LuTX, rates of recurrence and survival based on this sample appear to be acceptable. This article is protected by copyright. All rights reserved. |
|
This article is protected by copyright. All rights reserved. |
|
KEYWORDS: adjuvant therapy, immunosuppression, lung cancer, lung transplantation, recurrence, survival |
|
Publikations ID: 27220108 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
